The Union Health Ministry on Saturday requested the Ministry of External Affairs (MEA) to contemplate contacting Bharat Biotech for the procurement of 8.1 lakh doses of Covaxin to be given to totally different countries as a goodwill gesture.
According to an workplace memorandum accessed by IANS, Under Secretary to the federal government, G.Okay. Pillai, alluded to the assembly held between the Secretary on the Department of Pharmaceuticals and the Foreign Secretary on Friday, whereby it emerged that the MEA would supply 8.1 lakh doses of Covaxin to totally different countries within the type of grant-in-aid as a goodwill gesture.
“In this regard, it is to inform that Bharat Biotech Limited is providing a total of 10 million (1 crore) doses of this vaccine to the Health Ministry for the ongoing Covid-19 vaccination drive in India. The price of the procured vaccine is Rs 295 per dose plus GST,” the workplace memorandum said.
It added, “The MEA may, accordingly, consider contacting Bharat Biotech for the procurement of the aforesaid 8.1 lakh doses of this vaccine, which may provide the said quantum at the above-mentioned price,” it added.
The Under Secretary stated that conserving in view the programmatic priorities of the continued vaccination drive in India, the quantum of doses ought to be procured by the Ministry of External Affairs from Bharat Biotech solely after January 22.
Besides, on January 12, Bharat Biotech had introduced that it has signed an settlement with Precisa Medicamentos for supplying Covaxin doses to Brazil.
Covaxin is a extremely purified and inactivated two-dose vaccine. The vaccine, together with Oxford-AstraZeneca’s Covishield, was administered to over 1.91 lakh folks throughout the nation on Saturday.
Covaxin, India’s indigenous Covid-19 vaccine developed by Bharat Biotech, is being made in collaboration with the Indian Council of Medical Research (ICMR)-National Institute of Virology (NIV). It is offered in multi-dose vials and may be saved at a temperature of 2-8-degree Celsius.
The Phase III human trials of Covaxin started in mid-November and is at present ongoing in 26,000 volunteers throughout India. It has been evaluated in roughly 1,000 topics in Phase I and Phase II medical trials, with promising security and immunogenicity outcomes.
It, nevertheless, has courted controversy because it acquired the approval from the drug regulator earlier this month. The approval given with out satisfactory efficacy knowledge drew flak from public well being advocacy teams, researchers, scientists and activists.